Search

The COVID-19 pandemic has had an important impact on the development and adoption of digital technologies for remote health care. Many of these digital health technologies are here to stay, as they greatly benefit care, but also research settings. This is especially true for people living with MND, since travelling,...

Amylyx Pharmaceuticals, Inc. today announced that the first participants have been dosed in their PHOENIX trial. This is a global study evaluating the safety and efficacy of the compound ‘AMX0035’ in people with ALS. The Phase 3 trial will be conducted at approximately 65 sites in Europe and the U.S. TRICALS is very...

The pharmaceutical company Ferrer has announced that the first patient has been enrolled in their ADORE (ALS Deceleration with ORal Edaravone) clinical trial. This Phase III trial will enrol about 300 patients across European countries. It will evaluate how effective and safe FNP122 (an oral formulation of edaravone...